BCAL Introduces Avantect Multi-Cancer Early Detection Test
Filed with ASX · · 2 pages · English
Summary by 6ix AI
BCAL Diagnostics Limited has announced the introduction of the Avantect Multi-Cancer Early Detection Test in Australia, starting with Sydney and Melbourne. This blood-based test detects cancer-associated signals across eight types of cancer, providing insights into the likely organ of origin. The test aims to enhance early detection capabilities, complementing existing cancer screening programs. BCAL plans a phased rollout to build market experience and patient access before a broader national expansion.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
BCAL Diagnostics Limited on 6ix
Earlier from BCAL Diagnostics
- Appendix 4E and Annual Report to shareholders
- BCAL Takes Interest in Genetic Signatures to 18.46%
- BCAL Secures Funding for FY2027 Update
- BCAL to Acquire Shares in Genetic Signatures
- BCAL Secures Funding for FY2027
Later from BCAL Diagnostics
- BREASTESTplus 2 clinically validated
- GSS: Response to Media Speculation & BCAL letter to GSS
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow BCAL Diagnostics into a list and get an email when it puts out news.
Follow BCAL Diagnostics